Wednesday, July 8, 2026

pharma · Diabetes Mellitus · Hemophilia A

Takeda

Takeda is a pharma organization headquartered in Cambridge, USA. Primary therapeutic focus areas include Diabetes Mellitus, Hemophilia A, Crohn's Disease, Hypertension, Type 2 Diabetes Mellitus. NovaPharmaNews links 1179

Cambridge, USA HQ
1993 Founded
1,617 Employees
NMPA registrant Type
Company details
Clinical program

161003

Phase 3 · mab · Alzheimer´s Disease

161003 for Alzheimer´s Disease is a Phase 3 program (mab) at Takeda with 1 ClinicalTrials.gov record(s).

← All Takeda projects Phase 3 mab terminated

Internal code 161003

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Takeda
Phase
Phase 3
Modality
mab
Indication
Alzheimer´s Disease
Status
terminated
Trials
1